Human immunodeficiency virus type 1 Vif protein binds to the Pr55(Gag) precursor

被引:91
作者
Bouyac, M
Courcoul, M
Bertola, G
Baudat, Y
Gabuzda, D
Blanc, D
Chazal, N
Boulanger, P
Sire, J
Vigne, R
Spire, B
机构
[1] INSERM,U372,F-13276 MARSEILLE 09,FRANCE
[2] FAC MED MONTPELLIER,INST BIOL,CNRS URA 1487,VIRAL & MOL PATHOGENESIS LAB,MONTPELLIER,FRANCE
[3] DANA FARBER CANC INST,DIV HUMAN RETROVIROL,BOSTON,MA 02115
关键词
D O I
10.1128/JVI.71.12.9358-9365.1997
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The Vif protein of human immunodeficiency virus type 1 is required for productive replication in peripheral blood lymphocytes. Previous reports suggest that vif-deleted viruses are limited in replication because of a defect in the late steps of the virus life cycle. One of the remaining questions is to determine whether the functional role of Vif involves a specific interaction with virus core proteins. In this study, we demonstrate a direct interaction between Vif and the pr55(Gag) precursor in vitro as well as in infected cells. No interaction is observed between Vif and the mature capsid protein. The pr55(Gag)-Vif interaction is detected (i) in the glutathione S-transferase system, with in vitro-translated proteins demonstrating a critical role of the NC p7 domain of the Gag precursor; (ii) with proteins expressed in infected cells; and (iii) by coimmunoprecipitation experiments. Deletion of the C-terminal 22 amino acids of Vif abolishes its interaction with the Pr55(Gag) precursor. Furthermore, point mutations in the C-terminal domain of Vif which have been previously shown to abolish virus infectivity and binding to cell membranes dramatically decrease the Gag-Vif interaction. These results suggest that the interaction between Vif and the Pr55(Gag) precursor is a critical determinant of Vif function.
引用
收藏
页码:9358 / 9365
页数:8
相关论文
共 49 条
[1]   PRODUCTION OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED RETROVIRUS IN HUMAN AND NONHUMAN CELLS TRANSFECTED WITH AN INFECTIOUS MOLECULAR CLONE [J].
ADACHI, A ;
GENDELMAN, HE ;
KOENIG, S ;
FOLKS, T ;
WILLEY, R ;
RABSON, A ;
MARTIN, MA .
JOURNAL OF VIROLOGY, 1986, 59 (02) :284-291
[2]   The human immunodeficiency virus type 1 Vpr transactivator: Cooperation with promoter-bound activator domains and binding to TFIIB [J].
Agostini, I ;
Navarro, JM ;
Rey, F ;
Bouhamdan, M ;
Spire, B ;
Vigne, R ;
Sire, J .
JOURNAL OF MOLECULAR BIOLOGY, 1996, 261 (05) :599-606
[3]  
BENICHOU S, 1994, J BIOL CHEM, V269, P30073
[4]   TRANSCOMPLEMENTATION OF VIF- HIV-1 MUTANTS IN CEM CELLS SUGGESTS THAT VIF AFFECTS LATE STEPS OF THE VIRAL LIFE-CYCLE [J].
BLANC, D ;
PATIENCE, C ;
SCHULZ, TF ;
WEISS, R ;
SPIRE, B .
VIROLOGY, 1993, 193 (01) :186-192
[5]   HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 VIF(-) MUTANT PARTICLES FROM RESTRICTIVE CELLS - ROLE OF VIF IN CORRECT PARTICLE ASSEMBLY AND INFECTIVITY [J].
BORMAN, AM ;
QUILLENT, C ;
CHARNEAU, P ;
DAUGUET, C ;
CLAVEL, F .
JOURNAL OF VIROLOGY, 1995, 69 (04) :2058-2067
[6]   Human immunodeficiency virus type 1 Vpr protein binds to the uracil DNA glycosylase DNA repair enzyme [J].
Bouhamdan, M ;
Benichou, S ;
Rey, F ;
Navarro, JM ;
Agostini, I ;
Spire, B ;
Camonis, J ;
Slupphaug, G ;
Vigne, R ;
Benarous, R ;
Sire, J .
JOURNAL OF VIROLOGY, 1996, 70 (02) :697-704
[7]   Phenotypically Vif(-) human immunodeficiency virus type 1 is produced by chronically infected restrictive cells [J].
Bouyac, M ;
Rey, F ;
Nascimbeni, M ;
Courcoul, M ;
Sire, J ;
Blanc, D ;
Clavel, F ;
Vigne, R ;
Spire, B .
JOURNAL OF VIROLOGY, 1997, 71 (03) :2473-2477
[8]   Characterization of human immunodeficiency virus type 1 Vif particle incorporation [J].
Camaur, D ;
Trono, D .
JOURNAL OF VIROLOGY, 1996, 70 (09) :6106-6111
[9]  
CARRIERE C, 1995, J VIROL, V69, P2366
[10]   HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 MA DELETION MUTANTS EXPRESSED IN BACULOVIRUS-INFECTED CELLS - CIS AND TRANS EFFECTS ON THE GAG PRECURSOR ASSEMBLY PATHWAY [J].
CHAZAL, N ;
GAY, B ;
CARRIERE, C ;
TOURNIER, J ;
BOULANGER, P .
JOURNAL OF VIROLOGY, 1995, 69 (01) :365-375